Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

We investigated sirolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis in patients with advanced hematological malignancies receiving myeloablative hematopoietic cell transplantation (HCT) from HLA-identical sibling donors. On the basis of pre-study stopping rules, the trial was closed to acc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2012-04, Vol.47 (4), p.581-588
Hauptverfasser:	Johnston, L, Florek, M, Armstrong, R, McCune, J S, Arai, S, Brown, J, Laport, G, Lowsky, R, Miklos, D, Shizuru, J, Sheehan, K, Lavori, P, Negrin, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adolescent Adult Bone marrow Bone marrow transplantation Cell Biology Child Child, Preschool Clinical trials Disease prevention Donors Drug therapy Fatalities Female Follow-Up Studies Graft versus host reaction Graft vs Host Disease - mortality Graft vs Host Disease - prevention & control Health aspects Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hemopoiesis Histocompatibility antigen HLA Humans Immunosuppressive Agents Internal Medicine Male Malignancy Medicine Medicine & Public Health Middle Aged Mycophenolate mofetil Mycophenolic acid Mycophenolic Acid - administration & dosage Mycophenolic Acid - analogs & derivatives original-article Portal vein Prophylaxis Public Health Rapamycin Risk factors Siblings sirolimus Sirolimus - administration & dosage Stem cell transplantation Stem Cells Thromboembolism Thrombosis Toxicity Transplantation Transplantation Conditioning Transplantation, Homologous Unrelated Donors Wound healing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!